



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/771,527	02/05/2004	Hiroshi Hagino	248573US0	3060
22850	7590 11/30/2005		EXAMINER	
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C. 1940 DUKE STREET ALEXANDRIA, VA 22314			LEITH, PATRICIA A	
			ART UNIT	PAPER NUMBER
			1655	

DATE MAILED: 11/30/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

•	Application No.	Applicant(s)			
	10/771,527	HAGINO, HIROSHI			
Office Action Summary	Examiner	Art Unit			
·	Patricia Leith	1655			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D.  - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be time will apply and will expire SIX (6) MONTHS from the, cause the application to become ABANDONE	I.  lety filed  the mailing date of this communication.  O (35 U.S.C. § 133).			
Status					
Responsive to communication(s) filed on 22 S     This action is FINAL. 2b) ☑ This 3) ☐ Since this application is in condition for allowed closed in accordance with the practice under	s action is non-final. ance except for formal matters, pro				
Disposition of Claims					
4)  Claim(s) 1-12 is/are pending in the application 4a) Of the above claim(s) 3-12 is/are withdraw 5)  Claim(s) is/are allowed. 6)  Claim(s) 1 and 2 is/are rejected. 7)  Claim(s) is/are objected to. 8)  Claim(s) are subject to restriction and/o	n from consideration.	-			
9) The specification is objected to by the Examin 10) The drawing(s) filed on 05 February 2004 is/an Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the E	re: a)⊠ accepted or b)⊡ objected or b)⊡ objected or awing(s) be held in abeyance. See ction is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date 9/16/04, 4/20/04.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:				

## **DETAILED ACTION**

## Election/Restrictions

Applicant's election with traverse of Group I, claims 1-2 in the reply filed on 7/28/05 is acknowledged. The traversal is on the ground(s) that all claims are directed to a 'vasodilator' and therefore should be searched co-extensively. This is not found persuasive because as pointed out in the original restriction requirement, although the products are vasodilators, the products are none-the-less patentably distinct products in that they are structurally and functionally distinct which would provide for different effects when administered to a patient.

The requirement is still deemed proper and is therefore made FINAL.

Applicant's election of the species of 'laver' in the reply filed on 9/22/05 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

Claims 1-2 directed toward 'laver', the elected species, were examined on their merits.

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1 and 2 are rejected under 35 U.S.C. 102(b) as being anticipated by Suetsuna et al. (JP 20000157226A) or Suetsuna et al. (JP 11080193 A).

Suetsuna et al. (JP 20000157226A) as well as Suetsuna et al. (JP 11080193 A) disclosed a hypotensive agent obtained by hydrolyzing laver peptides with pepsin (see English abstract).

Thus, Suetsuna et al. anticipate the claimed invention.

No Claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patricia Leith whose telephone number is (571) 272-0968. The examiner can normally be reached on Monday - Thursday 8:30am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Terry McKelvey can be reached on (571) 272-0775. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Patricia Leith Primary Examiner Art Unit 1655

11/28/05